一项多中心研究,评估经典阿育吠陀药物 Vyaghri Haritaki 对支气管哮喘的疗效和安全性

Pub Date : 2024-02-21 DOI:10.56042/ijtk.v23i2.6532
Milind Suryawanshi, V. B. Kumavat, P. Dua, B. Yadav, S. Khanduri, Pallavi S. Mundada, R. Singhal, Rakesh Kumar, Narayanam Srikanth
{"title":"一项多中心研究,评估经典阿育吠陀药物 Vyaghri Haritaki 对支气管哮喘的疗效和安全性","authors":"Milind Suryawanshi, V. B. Kumavat, P. Dua, B. Yadav, S. Khanduri, Pallavi S. Mundada, R. Singhal, Rakesh Kumar, Narayanam Srikanth","doi":"10.56042/ijtk.v23i2.6532","DOIUrl":null,"url":null,"abstract":"Bronchial asthma (vis-à-vis Tamaka Swasa in Ayurveda) is a chronic inflammatory disorder of the airway. Multiple Ayurvedic formulations are prescribed by Ayurveda physicians for Tamak Swasa . Vyaghri Haritaki is one such commonly prescribed poly herbal classical Ayurvedic formulation. A multicentre single-arm study was conducted at three Ayurveda Research Institutes in India to explore the effect and tolerability of Vyaghri Haritaki , a classical Ayurvedic medicine, on bronchial asthma ( Tamaka Swasa ). One forty seven patients between 18 and 60 years diagnosed with bronchial asthma showing a positive test of reversibility of airway obstruction were enrolled. Patients with peak expiratory flow rate (PEFR) < 50% and/ or forced expiratory volume in the first second (FEV1) < 50% of the predicted value and other major co-morbidities were excluded. 10 g Vyaghri Haritaki twice a day with lukewarm water was given for 12 weeks (84 days). Changes in the clinical symptoms (Asthma Control Questionnaire), quality of life (St. George Respiratory Questionnaire), respiratory function (peak expiratory flow rate and forced expiratory volume in one second), and haematological and biochemical parameters were compared before and after the treatment. Data of 142 participants were analysed which revealed significant improvement in PEFR [Baseline 301.7 litre/minute and 84 th Day 334.85 litre/minute (p<0.001)], FEV1 [Baseline 1.83 litres and 84 th Day 2.12 litres (p<0.001)], Asthma Control Questionnaire [Baseline 2.95 and 84 th Day 1.43 (p<0.001)], and the total score of the St. George Respiratory Questionnaire [Baseline 50.46 and 84 th Day 30.74 (p<0.001)]. No adverse events were reported during the study. Vyaghri Haritaki may prove beneficial in improving the pulmonary function, overall symptoms, and quality of life of patients with bronchial asthma which is well tolerated.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A multi-centre study to evaluate the effect and safety of a classical Ayurveda medicine Vyaghri Haritaki in bronchial asthma\",\"authors\":\"Milind Suryawanshi, V. B. Kumavat, P. Dua, B. Yadav, S. Khanduri, Pallavi S. Mundada, R. Singhal, Rakesh Kumar, Narayanam Srikanth\",\"doi\":\"10.56042/ijtk.v23i2.6532\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bronchial asthma (vis-à-vis Tamaka Swasa in Ayurveda) is a chronic inflammatory disorder of the airway. Multiple Ayurvedic formulations are prescribed by Ayurveda physicians for Tamak Swasa . Vyaghri Haritaki is one such commonly prescribed poly herbal classical Ayurvedic formulation. A multicentre single-arm study was conducted at three Ayurveda Research Institutes in India to explore the effect and tolerability of Vyaghri Haritaki , a classical Ayurvedic medicine, on bronchial asthma ( Tamaka Swasa ). One forty seven patients between 18 and 60 years diagnosed with bronchial asthma showing a positive test of reversibility of airway obstruction were enrolled. Patients with peak expiratory flow rate (PEFR) < 50% and/ or forced expiratory volume in the first second (FEV1) < 50% of the predicted value and other major co-morbidities were excluded. 10 g Vyaghri Haritaki twice a day with lukewarm water was given for 12 weeks (84 days). Changes in the clinical symptoms (Asthma Control Questionnaire), quality of life (St. George Respiratory Questionnaire), respiratory function (peak expiratory flow rate and forced expiratory volume in one second), and haematological and biochemical parameters were compared before and after the treatment. Data of 142 participants were analysed which revealed significant improvement in PEFR [Baseline 301.7 litre/minute and 84 th Day 334.85 litre/minute (p<0.001)], FEV1 [Baseline 1.83 litres and 84 th Day 2.12 litres (p<0.001)], Asthma Control Questionnaire [Baseline 2.95 and 84 th Day 1.43 (p<0.001)], and the total score of the St. George Respiratory Questionnaire [Baseline 50.46 and 84 th Day 30.74 (p<0.001)]. No adverse events were reported during the study. Vyaghri Haritaki may prove beneficial in improving the pulmonary function, overall symptoms, and quality of life of patients with bronchial asthma which is well tolerated.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.56042/ijtk.v23i2.6532\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.56042/ijtk.v23i2.6532","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

支气管哮喘(相对于阿育吠陀中的 Tamaka Swasa)是一种慢性气道炎症性疾病。阿育吠陀医生为 Tamak Swasa 开出了多种阿育吠陀处方。Vyaghri Haritaki 是一种常用的多草药经典阿育吠陀配方。印度的三家阿育吠陀研究所开展了一项多中心单臂研究,探讨经典阿育吠陀药物 Vyaghri Haritaki 对支气管哮喘(Tamaka Swasa)的疗效和耐受性。研究人员招募了 147 名 18 至 60 岁的支气管哮喘患者,这些患者的气道阻塞可逆性测试结果呈阳性。排除了呼气峰流速(PEFR)小于预测值的 50%和/或第一秒用力呼气容积(FEV1)小于预测值的 50%以及合并其他重大疾病的患者。每天两次用温水冲服 10 克 Vyaghri Haritaki,连续服用 12 周(84 天)。比较了治疗前后临床症状(哮喘控制问卷)、生活质量(圣乔治呼吸问卷)、呼吸功能(呼气峰值流速和一秒内用力呼气量)以及血液和生化指标的变化。对 142 名参与者的数据进行分析后发现,PEFR [基线为 301.7 升/分钟,第 84 天为 334.85 升/分钟(p<0.001)]、FEV1 [基线为 1.83 升,第 84 天为 2.12升(p<0.001)]、哮喘控制问卷[基线为2.95,第84天为1.43(p<0.001)]和圣乔治呼吸问卷总分[基线为50.46,第84天为30.74(p<0.001)]。研究期间未报告任何不良事件。Vyaghri Haritaki 可改善支气管哮喘患者的肺功能、整体症状和生活质量,且耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享
查看原文
A multi-centre study to evaluate the effect and safety of a classical Ayurveda medicine Vyaghri Haritaki in bronchial asthma
Bronchial asthma (vis-à-vis Tamaka Swasa in Ayurveda) is a chronic inflammatory disorder of the airway. Multiple Ayurvedic formulations are prescribed by Ayurveda physicians for Tamak Swasa . Vyaghri Haritaki is one such commonly prescribed poly herbal classical Ayurvedic formulation. A multicentre single-arm study was conducted at three Ayurveda Research Institutes in India to explore the effect and tolerability of Vyaghri Haritaki , a classical Ayurvedic medicine, on bronchial asthma ( Tamaka Swasa ). One forty seven patients between 18 and 60 years diagnosed with bronchial asthma showing a positive test of reversibility of airway obstruction were enrolled. Patients with peak expiratory flow rate (PEFR) < 50% and/ or forced expiratory volume in the first second (FEV1) < 50% of the predicted value and other major co-morbidities were excluded. 10 g Vyaghri Haritaki twice a day with lukewarm water was given for 12 weeks (84 days). Changes in the clinical symptoms (Asthma Control Questionnaire), quality of life (St. George Respiratory Questionnaire), respiratory function (peak expiratory flow rate and forced expiratory volume in one second), and haematological and biochemical parameters were compared before and after the treatment. Data of 142 participants were analysed which revealed significant improvement in PEFR [Baseline 301.7 litre/minute and 84 th Day 334.85 litre/minute (p<0.001)], FEV1 [Baseline 1.83 litres and 84 th Day 2.12 litres (p<0.001)], Asthma Control Questionnaire [Baseline 2.95 and 84 th Day 1.43 (p<0.001)], and the total score of the St. George Respiratory Questionnaire [Baseline 50.46 and 84 th Day 30.74 (p<0.001)]. No adverse events were reported during the study. Vyaghri Haritaki may prove beneficial in improving the pulmonary function, overall symptoms, and quality of life of patients with bronchial asthma which is well tolerated.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信